Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
    • Recent News
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Analyst Coverage
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Independent Directors
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results

May 15, 2019

DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering

May 8, 2019

DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split

May 7, 2019

DelMar Presents Data Supporting VAL-083 as Potential Treatment for Pediatric Brain Tumors at SNO Pediatric Neuro-Oncology Conference

May 6, 2019

DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board

Apr 4, 2019

DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083

Apr 3, 2019

DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM

Feb 20, 2019

DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results

Feb 12, 2019

DelMar Pharmaceuticals Receives Nasdaq Listing Extension

Feb 7, 2019

DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting

Nov 20, 2018
RSS
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...28
    © 2021 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information